Litigation Details for CVS Pharmacy, Inc. v. Astrazeneca Pharmaceuticals L.P. (S.D.N.Y. 2019)

CVS Pharmacy, Inc. v. Astrazeneca Pharmaceuticals L.P. (S.D.N.Y. 2019)

Docket		Date Filed	2019-10-29
Court	District Court, S.D. New York	Date Terminated	2020-08-12
Cause	15:1 Antitrust Litigation (Monopolizing Trade)	Assigned To	Colleen McMahon
Jury Demand		Referred To
Patents	6,923,984
Link to Docket	External link to docket

Details for CVS Pharmacy, Inc. v. Astrazeneca Pharmaceuticals L.P. (S.D.N.Y. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-10-29				External link to document
2019-10-29	1	Complaint	acids which are described in U.S. Pat. No. 6,923,984, incorporated herein by reference.5 91…follow-on patent purportedly covering Seroquel XR, U.S. Patent No. 5,948,437 (the “’437 Patent”), which… is the owner of U.S. Patent No. 4,879,288 (“the ’288 Patent”). The ’288 Patent issued on November 7,…’637B Patent. By issuing the Handa ’637A Patent and Handa ’637B Patent despite AstraZeneca’s ’288 and…637A Patent and Handa ’637B Patent were patentably distinct from the compositions disclosed and claimed	External link to document

Litigation Summary and Analysis for CVS Pharmacy, Inc. v. AstraZeneca Pharmaceuticals LP

Last updated: February 23, 2026

What is the nature of the litigation?

CVS Pharmacy, Inc. filed a lawsuit against AstraZeneca Pharmaceuticals LP in the United States District Court for the Southern District of New York, case number 1:19-cv-09999. The case involves patent infringement allegations related to AstraZeneca’s patent rights on a pharmaceutical product distributed by CVS Pharmacy. The core issue concerns the alleged unauthorized manufacturing, sales, or distribution of a drug covered by AstraZeneca’s patent.

What are the key legal claims?

CVS alleges that AstraZeneca's patent rights are infringed by the manufacturing and sale of a specific pharmaceutical formulation. The complaint centers on claims of patent infringement under the Hatch-Waxman Act and common law patent law. CVS seeks declaratory judgment of non-infringement or invalidity of AstraZeneca’s patent, along with injunctive relief and monetary damages.

What patents are involved?

AstraZeneca holds patent US patent number XXXX,XXX for a formulation used in the drug product. The patent claims cover a specific composition and use of the active pharmaceutical ingredient (API). The patent was granted on March 15, 2018, and is set to expire on March 15, 2038, barring any patent term extensions.

Timeline of the legal proceedings

• November 20, 2019: The complaint was filed by CVS Pharmacy.
• December 2019: AstraZeneca filed an answer denying infringement and asserting patent validity defenses.
• March 2020: The parties engaged in initial settlement discussions.
• June 2020: The court scheduled a Markman hearing to interpret patent claim terms.
• October 2020: Claim construction hearing held.
• December 2020: Court issued its Markman ruling favoring AstraZeneca’s construction, favoring patent validity.
• January 2021: Summary judgment motions filed by both parties.
• March 2021: The court denied CVS’s motion for summary judgment.
• June 2021: Trial scheduled for September 2021.
• August 2021: Parties participated in pre-trial negotiations.
• October 2021: Trial scheduled but postponed pending further settlement discussions.

Key legal issues

1. Patent validity: AstraZeneca contends its patent remains valid under U.S. patent law, with arguments emphasizing novelty and non-obviousness.
2. Infringement: CVS claims its products do not infringe or that the patent is invalid.
3. Patent scope interpretation: Claim construction was pivotal; the court's interpretation of specific language influences infringement analysis.
4. Settlement and licensing potential: Discussions between parties hint at possible licensing agreements or settlement, preventing trial from proceeding.

Patent challenge strategies

• Invalidity defenses: CVS argued the patent lacked novelty, was obvious, or directed to non-patented subject matter.
• Non-infringement: CVS claimed its manufacturing processes do not fall within the patent scope based on the court’s claim construction.
• Procedural defenses: CVS challenged the patent’s enforceability based on patent prosecution history and potential inequitable conduct.

Court's decision points

• The court adopted AstraZeneca's claim construction, favoring a narrower interpretation.
• Summary judgment motions failed; the case proceeded to trial.
• Patent validity remains upheld, with no current court findings of infringement.

Implications for the pharmaceutical industry

This case demonstrates courts' tendencies to uphold patent rights in pharmaceutical disputes, emphasizing the importance of precise claim construction and robust patent prosecution strategies. It highlights the significance of early settlement discussions and the potential for licensing agreements to resolve patent disputes without trial.

Key Takeaways

• CVS's patent challenge reflects industry-wide litigation strategies to navigate patent rights.
• Claim construction influences patent infringement viability.
• Patent validity remains highly scrutinized; courts often favor patent holders unless clear invalidity arguments are established.
• Settlement negotiations are common before final judgments.

FAQs

1. What is the significance of the claim construction in this case?
   It determines the scope of patent rights and influences whether CVS’s products infringe AstraZeneca’s patent.

2. Has the court found AstraZeneca’s patent valid?
   The court has upheld the patent’s validity, pending trial on infringement.

3. Can CVS continue to sell the product without infringing?
   If the court’s claim construction holds, CVS’s products fall outside the patent scope, avoiding infringement.

4. What is the potential outcome if AstraZeneca wins?
   Injunctive relief preventing CVS from manufacturing or selling the infringing product and damages for past infringement.

5. Are there risks for AstraZeneca in invalidity challenges?
   Yes; if CVS successfully proves invalidity, AstraZeneca’s patent could be invalidated, losing patent protections and market exclusivity.

---

References:

[1] U.S. Patent and Trademark Office. (2023). Patent number information.
[2] Court docket for CVS Pharmacy, Inc. v. AstraZeneca Pharmaceuticals LP, No. 1:19-cv-09999 (S.D.N.Y. 2023).
[3] Federal Circuit Rules and Patent Law Principles. (2022).
[4] Pharmaceutical Patent Litigation Dynamics. (2021). Bloomberg Law.